DiabetesDataDigital medicine
Diabetes, metabolism, hormones. Evidence and opinions at a glance.
Evidence and innovation, clearly put in context: what has been published, what is new on the market and what it means for people and care.
For many people with diabetes, daily treatment is an emotional burden. It is common, and it is not the same as depression, even though the two can occur together. This article puts in context what can help, and where the evidence still has gaps.
Read
Semaglutide and tirzepatide make a marked weight loss possible. In the direct comparison of the doses studied, the loss was greater with tirzepatide. The data on benefit for the heart and circulation, however, come from different patient groups and trials.
Read
Pregnant women with diabetes who use CGM in addition to capillary glucose checks have children with macrosomia less often. That is the finding of a meta-analysis of 17 randomised trials with 2,672 participants. According to trial sequential analysis, however, the amount of data is not yet enough.
Read
For 26 weeks, 283 adults with type 2 diabetes who were not using insulin, and whose HbA1c was at least 7.5 percent, received either real-time CGM or usual care. The trial was run in US primary care. In Austria, Germany and Switzerland, insurers cover CGM only for people on insulin, so this group is usually not covered.
Read
Since 1 September 2026, CamAPS Liberty has been available in Austria, Germany and Switzerland. According to the manufacturer, carbohydrate estimates and meal boluses are usually not needed. It is intended for people with type 1 diabetes aged 13 and older, and not for use in pregnancy.
Read
With type 1 diabetes, the sensor, the pump and the clinic produce data every day, usually in separate systems. A blockchain would not store the values themselves. It would only record who was granted access. The evidence for that is thin, and the EU is pursuing similar aims without a blockchain.
ReadDMC³ connects medicine and digital health for people with chronic conditions. We advise companies and health service providers on the development, scientific assessment and market introduction of digital health products, prepare publicly available studies and data in an understandable way, hold participations in companies in this field, and keep you up to date with news and stories.
Development, scientific evaluation and market introduction of digital health products
Preparing and contextualising publicly available studies and market data
in companies in digital health
Next is Focus, in four areas. It covers studies and official announcements, personal health data, new products and approvals, and prompts for daily life, starting with sleep.
Read the outlook
Themes
Sensors, pumps, apps and systems. What is new, and what it means for care.
Published studies, placed in context, with benefits and limits.
We work in four defined areas, where medical need, technical feasibility and ethical responsibility have to fit together.
We put published studies and official announcements on digital health in context and name their benefits and limits.
We stand for a self-determined and transparent approach to personal health data. We report on approaches that aim to strengthen security and control of personal data through encryption and distributed networks.
New products and approvals, described plainly, with their status in Europe and Switzerland.
Evidence based prompts for daily life, starting with sleep.
Care in which technology lightens the load and makes time for human attention and clinical judgement.
Mission
Technology should lower barriers, so that what matters has room: clinical skill and human attention in care.
We connect technical innovation with human attention. We show which technologies can strengthen people with diabetes and ease the work of those who treat them, and where evidence is still missing.
Write to us
If you would like to talk, we will be glad to hear from you.
